Centrum Diagnostyki I Mikrochirurgii Oka Lens Sp. z o.o.
- Address
- lock Available on a paid plan
Eye Diseases
The centre concentrates on eye diseases such as age‑related macular degeneration, diabetic macular edema, and retinal vein occlusion. Clinical studies are designed to evaluate new therapies, compare existing treatments, and improve visual acuity for affected patients.
- Age‑related macular degeneration (wet and dry)
- Diabetic macular edema
- Diabetic retinopathy
- Retinal vein occlusion
- Myopic choroidal neovascularization
Centrum Diagnostyki I Mikrochirurgii Oka Lens supports a multidisciplinary team of five investigators conducting fifteen trials, emphasizing patient‑centered care and advancing ophthalmic research in Olsztyn, Poland.
Ocular Physiological Phenomena
Research also explores ocular physiological phenomena such as retinal fluid dynamics and complement system activity, seeking to understand disease mechanisms and assess how novel agents influence visual function and disease biomarkers.
- Complement pathway inhibition studies
- Dosing frequency‑response evaluations
- Innovative drug‑delivery systems
- Pre‑filled syringe usability assessments
- Port delivery system performance
Located in Olsztyn, the site collaborates with local healthcare professionals to ensure rigorous trial conduct and high‑quality data collection for advancing eye‑health science.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Eyebiotech Limited1active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyebiotech Limited3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Diagnostyki I Mikrochirurgii Oka Lens Sp. z o.o.
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 6 | Unknown | 2023-09-13 | 2026-06-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.